3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
5
Gastro-enteropancreatic neuroendocrine tumor
2
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
2
fludarabine
1
Tumor Burden
1
Quality of Life
1
Magnetic Resonance Spectroscopy
1
Histocompatibility Testing
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Everolimus
1
Cyclophosphamide
1
Blood Specimen Collection
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymus Neoplasms
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled